Policy & Regulation
Anixa Biosciences reveals final data from Phase one clinical trial of investigational breast cancer vaccine at 2025 San Antonio Breast Cancer Symposium
12 December 2025 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company, on Thursday announced final data from the Phase one clinical trial of its investigational breast ca...
Amgen's UPLIZNA receives US FDA approval
12 December 2025 - Amgen Inc (NASDAQ:AMGN), an American multinational biopharmaceutical company, announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for ...
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
12 December 2025 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Thursday that it has met its primary endpoint in the Phase 1b clinical study of mazduti...
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
11 December 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted priority review to its supple...
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
11 December 2025 - Physiomics plc (AIM:PYC), a mathematical modelling, data science and biostatistics company, said on Thursday that it has signed a new contract with Swiss biotechnology company Numab...
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
11 December 2025 - Chinese biotechnology company OTR Therapeutics announced on Thursday that it has signed a multi-programme strategic collaboration and licence agreement with Zealand Pharma A/S (CPH:...